People without water, electricity and money are not exactly Big Pharma's target demographic.
Wild boar injected with α2-antagonist atipamezole (Antisedant® 5 mg/ml, Orion Pharma, Finland, target dose 0.20 mg/kg) were excluded from the statistics.
Same goes for another easy target: Big Pharma.
One of its programs is Therapeutics for Rare and Neglected Diseases (TRND), launched in 2009 with the aim of helping NIH and university scientists develop treatments for disorders that pharma has ignored because the target patient population is too small or poor.
Researchably: Targeting medical research, pharma sales and outreach teams, the startup provides a research-based medical advice system.
From Alzheimer's disease and the obesity epidemic to the chronic health effects of certain viral infections, scientists in academia and big pharma are seeking new therapeutic targets and strategies to tackle these diseases.
Strain-specific resistance to Micafungin (Astellas Pharma, Tokyo), a compound that targets fungal cell wall biosynthesis was tested by culturing cells at 25°C in 200 μL of low-nitrogen, with 150 nM Micafungin or a solvent control (DMSO).
InsideDNA plans to help research and pharma teams identify the best drug target by using machine learning to analyze massive genetic datasets and identify likely drug targets.
Many more are in the pipeline, and Foundation Medicine is working on ways to better inform doctors and pharma companies as to how to target new drugs based on gene sequencing.
Pharma now understands the value of targeting specific genetic abnormalities even in small populations.
In some cases, SRPmotif identified pharma-motifs from over hundreds of target proteins within 10 minutes.
